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Non-Alcoholic Steatohepatitis
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CA, USA
Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in adults and children world-
wide. NAFLD has become a severe health issue and it can progress towards a more severe form of the disease, the non-alcoholic 
steatohepatitis (NASH). A combination of environmental factors, host genetics, and gut microbiota leads to excessive accumula-
tion of lipids in the liver (steatosis), which may result in lipotoxicity and trigger hepatocyte cell death, liver inflammation, fibro-
sis, and pathological angiogenesis. NASH can further progress towards liver cirrhosis and cancer. Over the last few years, cell-de-
rived extracellular vesicles (EVs) have been identified as effective cell-to-cell messengers that transfer several bioactive molecules 
in target cells, modulating the pathogenesis and progression of NASH. In this review, we focused on recently highlighted aspects 
of molecular pathogenesis of NASH, mediated by EVs via their bioactive components. The studies included in this review sum-
marize the state of art regarding the role of EVs during the progression of NASH and bring novel insight about the potential use 
of EVs for diagnosis and therapeutic strategies for patients with this disease. 
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INTRODUCTION
All international and national health organizations report that 
obesity has doubled since 1982. In 2014 over 1.9 billion adults 
were overweight and of these over 600 million were obese 
worldwide. This makes obesity a serious pandemic and public 
health problem [1-3]. Importantly, childhood obesity has tri-
pled in the last 30 years and the World Health Organization re-
ports that 42 million children under the age of five were over-
weight or obese in 2013 [4,5]. The clinical relevance of obesity 
derives from the fact that obesity is associated with several 
metabolic risk factors that define the metabolic syndrome 
(MetS) [6]. MetS is strongly associated with the development of 
comorbidities, including cardiovascular diseases, diabetes as 
well as non-alcoholic fatty liver disease (NAFLD) [7-10]. 
 NAFLD is one of the most common causes of chronic liver 
disease (CLD) and liver-related morbidity and mortality 
worldwide. Currently, NAFLD has an estimated prevalence in 
the general population of 20% to 30% in Western Countries 
and 5% to 18% in Asia, and it is predicted to increase over time 
[11-14]. An additional dramatic increase of NAFLD has been 
associated with obesity and excessive fructose consumption 
[15,16]. Notably, the overall prevalence of childhood NAFLD 
has reached about 10%, with a worrisome prevalence rate of 
17% in teenagers [17]. This prevalence dramatically increases 
up to 40% to 70% among obese children [18,19]. A subset of 
3% to 5% of NAFLD patients can develop early non-alcoholic 
steatohepatitis (NASH) [20,21], characterized by lobular and 
portal inflammatory infiltrates of monocyte-derived macro-
phages, neutrophils and lymphocytes; various degree of fibro-
sis, hepatocyte cell death and pathological angiogenesis. With 
the progression of the disease to advanced NASH, extensive fi-
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brosis is associated with high risk of developing cirrhosis, liver 
failure, portal hypertension and/or hepatocellular carcinoma 
(HCC), the third leading cause of cancer death worldwide 
[22,23]. Advanced fibrosis and cirrhosis are the principal 
causes of liver-related morbidity and mortality. In a recent 
study published by Wong and colleagues [24] on the annual 
trends of new liver transplant waitlist registrations they report-
ed that from 2004 to 2013 NASH, as cause of CLD, showed an 
increase of almost 170% in the number of new waitlist registra-
tions, compared to other CLDs such as alcoholic liver disease 
or hepatitis C virus. This makes NASH the second leading eti-
ology of CLD in new waitlist registrations for liver transplant 
and projections show that NASH will become the leading cause 
of liver transplantation by 2020 [24,25]. 
 The most accepted concept on the pathogenesis of NAFLD 
involves multiple concomitant events or ‘hits’ associated with 
a crosstalk between environment, host genetics and gut mi-
crobiota [26,27]. In this scenario, stressed or damaged cells re-
lease various dangerous signals that influence and drive 
NASH-related outcomes such as isolated steatosis, sterile in-
flammation, fibrosis, pathological angiogenesis, and progres-
sive liver injury [26,28]. In this review, we will focus and un-
cover novel insights on cell-derived extracellular vesicles 
(EVs) as damage-associated molecular signals involved in the 
molecular pathogenesis of NASH. We will describe studies re-
porting the EV-driven signaling and molecular pathways re-
lated to the initial and advanced events involved during the 
progression of NASH. We will describe the EV genesis from 
cells exposed to toxic agents and the reported effects on func-
tionality and activity of the target cells. 
EXTRACELLULAR VESICLES AND NAFLD 
PROGRESSION
Different populations of EVs at play 
EVs (or exovesicles, as most recently named) are a heteroge-
neous population of small membrane-surrounded structures 
released by cells in the extracellular environment as well as in 
the bloodstream and are involved in normal physiology as well 
as in the pathobiology of disease [29-32]. EVs are effective 
communicators that are generated by a cell of origin or paren-
teral cell and can act on a number of target cells in an autocrine 
or paracrine pathway in the extracellular environment where 
they are released as well as in an endocrine manner, acting as 
long range signals [33-36]. EVs shuttle a variety of bioactive 
molecules that may reflect the cell of origin as well as the spe-
cific stress that induces their formation and release. They trans-
port and transfer in target cells bioactive molecules, including 
mRNA, different non-coding RNAs (microRNA, longRNA mi-
tochondrial associated tRNA, small nucleolar RNA, small nu-
clear RNA, Ro associated Y-RNA, vault RNA, and Y-RNA), 
proteins, DNA and lipids that influence and modulate various 
cell responses [37,38]. EVs have been divided in three main 
categories: exosomes, ectosomes (or microparticles [MPs] or 
microvesicles) and apoptotic bodies (Fig. 1) [29,39,40]. Howev-
er, several reports have shown that these subpopulations have 
one or more characteristics in common and a clear distinction 
among the different categories is still not completely possible. 
 Exosomes are approximately 30 to 100 nm in size and origi-
nate from inward budding of the membrane of late endosoma 
compartments in the cytosol of cells. The fusion of endosomal 
compartment with the plasma membrane facilitate the release 
of exosomes that contain proteins, non-coding RNA (miRNA, 
long-RNA) and RNA interfering. Several studies have identi-
fied some exosomal membrane proteins, such as tetraspanins, 
CD63, CD81 and CD9 or TSG101 and Alix [39,41].
 Ectosomes are approximately 100 to 1,000 nm in size and are 
release from outward budding and blebbing of the plasma 
membrane directly in the extracellular space [29]. Most ecto-
somes express phosphatidylserine on the outer leaflet of the 
membrane, allowing their detection. However, a subpopulation 
of ectosomes does not express phosphatidylserine. For this rea-
son different labeling approaches and cell-specific markers are 
used to detect this subpopulation of EVs. Ectosomes carry a 
variety of different bioactive molecules, such as lipid, proteins, 
non-coding RNA and mRNA that can be shuttled into the tar-
get cells where ectosomes are efficiently internalized and in-
duce a variety of different cell responses [34,42-44]. 
 Apoptotic bodies are the largest EVs with a diameter be-
tween 500 to 4,000 nm [45]. Similarly to ectosomes they are 
released by blebbing of the plasma membrane of the apoptotic 
cells and they express phosphatidylserine on their surface [46]. 
Differently from exosomes and ectosomes, apoptotic bodies 
carry cell organelles, DNA fragments and histones [47,48]. 
Common markers of apoptotic bodies include complement 
component C3b and thrombospondin [49]. 
Lipotoxicity as a trigger for release of EVs
Lipotoxicity refers to a process by which accumulation of cer-
tain toxic lipids such as saturated free fatty acids (SFA), free 
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cholesterol, or ceramide and other sphingolipid among others 
in hepatocytes triggers various molecular pathways of cell 
stress and eventually results in cell death have evolved as a key 
event during NAFLD progression [50-52]. Elegant studies 
have shown that hepatocytes exposed to the SFA palmitic 
acid—lipotoxic lipid abundantly present in circulation of pa-
tients with NASH [53,54]—produce and release large quanti-
ties of EVs that may act on various target cells and contribute 
to key processes involved in NAFLD pathogenesis, including 
immune reactions, angiogenesis, and fibrosis (Fig. 2). 
EVs in liver pathological angiogenesis
Liver pathological angiogenesis consists in the development of 
an abnormal angioarchitecture during the progression of pro-
gressive CLDs, including metabolic-related liver diseases as 
NASH. The clinical relevance of pathological angiogenesis in 
NASH is associated with the evidence that pathological neoves-
sel formation drives hepatic fibrogenic progression and leads to 
the development of cirrhosis and related complications, such as 
HCC [55,56]. Pathological angiogenesis occurring during a 
CLD is primarily regulated by concomitant liver events that in-
volved complex cell-to-cell interaction and release of various 
pro-angiogenic factors in the liver microenvironment [57]. 
Several elegant studies have reported a role of EVs in activation 
of endothelial cells (ECs) and promotion of angiogenesis. In 
our previous studies we have demonstrated that hepatocyte-
derived EVs released during lipotoxicity have potent pro-an-
giogenic effects and promote EC activation in a Vanin-1-medi-
ated internalization [34]. In a pioneered study by Witek et al. 
[58], they showed that platelet-derived growth factor BB stimu-
lated myofibroblast-like hepatic stellate cells (HSCs) and reac-
tive cholangiocytes, release MPs that contain active Sonic 
hedgehog (Shh) and Indian hedgehog (Ihh)—two of the pro-
teins of the signaling pathway family of hedgehog. The same 
authors showed that plasma and bile level of Hh-containing 
MPs were elevated in chronic biliary fibrosis and bile duct liga-
tion rats, respectively. MPs carrying Hh molecules induced a 
pro-angiogenic switch in sinusoidal ECs, followed by in vivo 
Apoptotic bodies
Size: 500–4,000 nm
Biogenesis: cell death
Markers:  phosphatidylserine, C3b, 
thrombospondin
Content:  cell organelles, DNA fragments, 
histones
Fig. 1. Extracellular vesicles at play. Extracellular vesicles (EVs) or exovesicles are membrane surrounded structures release by 
cells both during physiological as well as under various stress conditions and they can be divided into exosomes, ectosomes, or 
microparticles, and apoptotic bodies. Exosomes (30 to 100 nm) are released via exocytosis through the fusion of multivesicular 
bodies (MVB) with plasma membranes. Ectosomes are vesicles 100 to 1,000 nm in size and they are released by direct blebbing/
budding from the plasma membrane. Apoptotic bodies are released by fragmentation of a cell during programmed cell death. 
Exovesicles express several cell specific and stress specific markers and carry a variety of bioactive molecules, including non-cod-
ing long and micro-RNAs, mRNA, lipids, and proteins. TSG101, tumor susceptibility gene 101.
Exosomes Ectosomes
(or microvesicles or microparticles)Size: 30–100 nm
Biogenesis: exocytosis
Markers:  CD81, CD9, TSG101, 
Alix, CD63
Content:  mRNA, lipids,  
proteins, non-coding RNA
Size: 100–1,000 nm
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Content: mRNA, non-coding RNA, lipids, proteins
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capillarization. In a more recent report by Lemoinne and col-
leagues [35], it has been demonstrated that portal myofibro-
blasts (PMFs) promote the formation of neo vessels triggering 
scarring development into the parenchyma in both CCl4-in-
duced liver fibrosis and NASH models. Through various ex-
perimental approaches, authors showed that activated PMFs 
release MPs that carry and transfer the pro-angiogenic factor 
vascular endothelial growth factor A (VEGF-A) to ECs, induc-
ing EC activation and tubulogenesis via VEGF-A receptor. 
However, the mechanism driving the release of VEGF-A by 
MPs was not further investigated by the authors of this pub-
lished study. In conclusion, EVs play a crucial role in liver an-
giogenesis and may link pathological angiogenesis and fibro-
genesis during the progression of NASH by transferring vari-
ous agents, including growth factors, hedgehog molecules, pro-
teins, and miRNAs. 
EVs in inflammatory responses
In a recent study published by Ibrahim et al. [36], they provide 
novel insights in the lipotoxicity-mediated release of hepato-
cyte-derived EVs during NASH development. Authors report 
that mixed lineage kinase 3 (MLK3) mediates the release of 
fat-laden hepatocyte-derived EVs that carry chemokine (C-X-
C motif) ligand 10 (CXCL10), a potent hepatocyte-derived 
macrophage chemoattractant [59]. These findings were con-
firmed by pharmacologically inhibiting MLK3, which resulted 
in a significant decrease in the amount of CXCL10 released by 
lipid-stressed hepatocytes. These observations highlight a 
novel role of CXCL10-enriched EVs in monocyte-derived 
macrophage recruitment and activation of resident Kupffer 
cells (the resident hepatic macrophages) during the progres-
sion of NASH (Fig. 3). Adipose tissue has also emerged as cru-
cial player in the development of hepatic steatosis and chronic 
low-grade inflammation, a key link between obesity and the 
associated metabolic dysregulation [33,60-62]. In line with 
this concept, one of our recent studies first-authored by Egu-
chi et al. [33] shows that mature differentiated adipocytes ex-
posed to palmitic acid resulted in the release of a marked 
amount of EVs that are potent chemoattractant factors that in-
duced migration of macrophages. Through various lines of ev-
idence, we showed that the release of EVs as chemotactic sig-
nals by adipocytes treated with palmitic acid was mediated by 
caspase-3 activation [33,34]. These findings identified adipo-
cyte-derived EVs as novel “find-me” signals linking adipocytes 
Fig. 2. Extracellular vesicles in the pathogenesis of fatty liver disease. During the process of lipotoxicity, hepatocytes release large 
quantities of extracellular vesicles (EVs) that may then act on various target cells in the local environment they are released con-
tributing to key processes involved in non-alcoholic fatty liver disease pathogenesis including immune modulation, angiogene-
sis, and fibrosis. Additionally, EVs may be released to the systemic circulation and can be potentially used to non-invasively 
monitoring the extent of liver injury. 
Liver
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Target cells
Extracellular vesicles
Fatty acids
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stress to macrophages recruitment. The EV-mediated cell-to-
cell communication is a central event in a multifactorial dis-
ease as NASH. 
EVs in liver fibrogenesis
Several studies have shown that advanced fibrosis and cirrho-
sis are crucial pathophysiological events of CLDs and lead to 
clinical life-threatening consequences [63-66]. Notably, ad-
vanced fibrosis has been reported to increase the risk of HCC 
25-fold [23,67]. Activated HSCs are the main cell type that in-
duce and sustain the extracellular matrix remodeling and col-
lagen deposition during liver fibrogenesis [68-71]. Among 
many factors, circulating miRNAs are pivotal regulators of 
HSC phenotype and several studies have identified miRNAs 
up-regulated in experimental models of NAFLD or activated 
HSC in vitro [72-75]. For an extensive and complete overview 
on the role of miRNAs in the pathogenesis of CLDs we recom-
mend other reviews [76-80]. In this paragraph we will high-
light some studies describing the role of EVs in liver fibrogen-
esis in NASH. A first study showing that HSCs can be activat-
ed by EVs was published by Kornek and colleagues [81]. Au-
thors described the role of T cells in the fibrolytic activation of 
HSCs [81]. In this study it was demonstrated that activated 
and apoptotic CD4+ and CD8+ T cells release MPs in the ex-
tracellular environment and in circulation that fuse with HSCs 
and transfer membrane molecules such as CD147, triggering 
the upregulation of fibrolytic molecules. The biological signifi-
cance of “horizontal transfer” of bioactive molecules by EVs 
has been demonstrated by various studies. Pro-fibrogenic con-
nective tissue growth factor (CCN2) has been identified exo-
somes packaged by activated HSCs and shuttled to other qui-
escent or activated HSCs as form of paracrine pro-fibrogenic 
activation during a liver injury [82]. On the other hand, a sec-
ond study showed that exosomes released by quiescent HSCs 
Fig. 3. Hepatocyte-derived extracellular vesicles released during lipotoxicity and their role in liver fibrosis and inflammation. 
Lipid-induced toxicity (lipotoxicity) due to over-accumulation of various toxic lipids in hepatocytes such as saturated free fatty 
acids induce the release of exovesicles in a process that may involved activation of caspases such as caspase-3 as well as stress-ac-
tivated kinases such MLK3, ROCK1. Liver-derived exovesicles carry several bioactive molecules (e.g., CXCL10, connective tis-
sue growth factor, Twist1) and non-coding small or long RNAs, such as miR-128. These signals are shuttled by exovesicles and 
can modulate inflammation and fibrogenesis by recruiting or activating macrophages and quiescent hepatic stellate cells (HSCs), 
respectively. Notably, anti-fibrotic factors can be also transferred into extracellular vesicles and lead to HSC inactivation. 
CXCL10, chemokine (C-X-C motif) ligand 10; MLK3, mixed lineage kinase 3; ROCK, Rho-associated coiled-coil-containing 
protein kinase 1; CCN, connective tissue growth factor.
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have an anti-fibrogenic potential by transferring Twist1, a 
transcription factor that activates miR-214 and results in 
CCN2 suppression [83]. The evidence that EVs can shuttle 
and deliver small or long non-coding RNA has sparked a great 
interest in the basic pathological mechanisms of liver fibrosis 
development. Notably, it has been demonstrated that EVs 
shred by hepatocytes exposed to palmitic acid shuttle miR-
128-3p into HSCs and induce a down-regulation of PPAR-
gamma, a central modulator of HSC quiescence (Fig. 3) [84-
87]. In a complex microenvironment such as the one present 
during NASH-related fibrogenesis, EVs released by several cell 
sources play a key role in the homeostasis and balance be-
tween pro-fibrogenic and anti-fibrogenic mechanisms. 
EVs as novel biomarkers to monitor liver injury in NASH
Currently, liver biopsy remains the gold standard procedure to 
distinguish simple steatosis from steatohepatitis. However, it is 
costly, invasive and carries some morbidity and a rare mortality 
risk [63]. The biogenesis and composition of EVs have suggest-
ed that they might be identified as novel non-invasive and reli-
able biomarkers for liver injury during NASH development. 
This concept is further supported by the evidence that EVs can 
be detected and isolated from a variety of biofluids, including 
serum and plasma samples both from experimental animal 
models and human patients with NASH [88-90]. Level of cir-
culating MP derived from CD14+ and invariant natural killer 
T (iNKT) cells were significantly elevated in patients with 
NAFLD/NASH, independently of alanine aminotransferase 
levels or histopathological markers of disease activity [91]. In 
line with these findings, a complete characterization of bioavail-
ability, composition, and origin of circulating EVs would indi-
cate whether EVs can be used to discriminate different CLDs 
or different disease stages during the progression of CLDs such 
as NASH. Experimental evidence supporting this concept has 
been shown in one of our recent reports. In an experimental 
model of diet-induced NAFLD, early- and advanced-NASH, 
we observed that level of blood EVs increased over time during 
the NASH progression and was strongly associated with some 
key outcomes of NASH, including the extent of liver fibrosis, 
angiogenesis, and cell death [92]. The bioavailability of EVs in 
biofluids is only one of the fascinating aspects of these effective 
“messengers.” Indeed, the composition of EVs suggests an ex-
traordinary potentiality for biomarker development. As a proof 
of this, miRNAs encapsulated in circulating EVs have increas-
ingly exhibited great potential to fulfill several criteria for being 
considered a good biomarker, such as specificity, sensitivity, ro-
bustness, predictivity, translatability, and non-invasiveness 
[90,93,94]. Circulating EVs isolated from murine models of ex-
perimental NASH were enriched in miR-122 and miR-192, two 
microRNAs abundantly expressed in the liver [95,96]. The level 
of these microRNAs increased in EVs and decreased in livers 
over time during NAFLD progression [92]. The release of these 
microRNAs from stressed or damaged hepatocytes in EVs dur-
ing NAFLD progression may provide an attractive explanation 
for the decreased expression level of miR-122 found in the liv-
ers of patients with advanced NAFLD [97], as well as early stage 
hepatocarcinogenesis from NASH in both an animal model 
and human tissue samples, as recently reported [98,99]. In ad-
dition to microRNAs, a complete proteomics analysis of circu-
lating EVs isolated from rodents with NASH vs. controls re-
vealed a unique disease-specific protein signature that can be 
employed as “barcode” for diagnostic novel strategies in NASH 
[92]. These findings provide important support to the develop-
ment of EV-based lab-on-a-chip devices [100] that can be used 
for “liquid biopsy” to introduce novel and non-invasive diag-
nostic strategies for NASH. 
CONCLUSIONS
In conclusion, we have highlighted several of the most recent 
and original studies reporting the role of EVs as link between 
lipotoxicity, inflammation, angiogenesis, and fibrosis, all key 
events in the pathogenesis of NASH. Evidence shows that EVs 
may act as or transfer damage-associated molecular patterns to 
target cells of the liver microenvironment and orchestrate 
many of the main pathological events occurring concurrently 
during the development of NASH. A second important aspect 
of EVs consists on the fate of EVs, either benign or malignant 
and this seems to depend on the phenotype of the cell of origin. 
 Future studies will need to further (1) dissect the mecha-
nisms of release of EVs by the parenteral cells in pathological 
conditions; (2) investigate additional functions of EVs during 
the pathogenesis of NASH; and (3) elucidate whether an im-
paired balance between “bad” and “good” EVs might be a po-
tential cause of many CLDs.
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